Equity · Healthcare
BioNTech SE (BNTX) perpetual futures
BioNTech SE is a German biotechnology company that researches, develops and markets immunotherapies for cancer and infectious diseases, with a pipeline of vaccine and immunotherapy candidates and partnerships with major pharmaceutical firms.
Price chart
Interactive TradingView chart
TradingView symbol NASDAQ:BNTX
Loads TradingView's third-party widget (about 1 MB) on demand.
Trading data
Perpetual market activity
0/1 live markets
Trading data
Perpetual market activity
Spot performance
Best venues for this underlying
Best liquidity
-Tightest spread
-Highest volume
-Next catalyst
Catalysts
Next catalyst
Catalysts
No unusual perp activity right now.
Research data
Analysts, filings and peer context
Research data
Analysts, filings and peer context
Estimates
6Company events
6Peer comparison
Similar listed perpsRevenue mix
Latest annualAnalysts
Price targets in USD| Consensus rating | Buy |
|---|---|
| Average 12-month price target | $122.33 |
| 12-month target range (low – high) | $105 – $140 |
| Ratings in the provider's consensus | 24 |
Price targets as of 2026-11-21
Analyst rating history
Ratings| Month | Strong buy | Buy | Hold | Sell | Strong sell |
|---|---|---|---|---|---|
| Nov 2026 | 1 | 13 | 7 | 0 | 0 |
| Oct 2026 | 1 | 13 | 7 | 0 | 1 |
| Sep 2026 | 1 | 14 | 5 | 0 | 1 |
| Aug 2026 | 1 | 14 | 5 | 0 | 1 |
| Jul 2026 | 1 | 14 | 5 | 0 | 1 |
| Jun 2026 | 1 | 14 | 5 | 0 | 0 |
| May 2026 | 1 | 13 | 6 | 0 | 1 |
| Apr 2026 | 1 | 13 | 5 | 0 | 1 |
| Mar 2026 | 1 | 14 | 5 | 0 | 0 |
| Feb 2026 | 1 | 15 | 5 | 0 | 0 |
| Jan 2026 | 1 | 15 | 5 | 0 | 0 |
| Dec 2025 | 1 | 14 | 5 | 0 | 0 |
Ownership
Institutional · 2026-Q2Reference market activity
BNTX-PERPPrice performance
11Insider activity
FY2026 Q4Insider transactions
25BioNTech CEO Ugur Sahin sold 63,209 Ordinary Shares in two open-market sales on Oct 8-9, 2026, at $92.31-$95.37 per share, leaving 0 shares owned after.
BioNTech SE CEO Ugur Sahin sold 24,000 ordinary shares at $95.8597 on Oct 7, 2026, leaving 63,209 shares owned.
BioNTech CEO Ugur Sahin sold 93,000 ordinary shares in two open-market transactions on Oct 5-6, 2026, at prices of $96.81-$97.23, leaving 87,209 shares held.
BioNTech SE CEO Ugur Sahin sold 34,000 ordinary shares in two open-market sales on Oct 1-2, 2026 at prices from $96.72 to $97.46, leaving 180,209 shares held.
BioNTech CEO Ugur Sahin sold 66,000 ordinary shares in two open-market transactions on Sept 29-30, 2026, at prices of $98.12-$98.26 per share. He held 214,209 shares after the sales.
BioNTech CEO Ugur Sahin sold 61,000 ordinary shares in two open-market sales on Sept 25-28, 2026, at $98.47-$98.69 per share, leaving 280,209 shares held.
BioNTech CEO Ugur Sahin sold 69,000 ordinary shares on Sept 23-24, 2026 at $98.99-$99.40 per share (two open-market S-Sale transactions). After the sales he owned 341,209 shares.
BioNTech CEO Ugur Sahin sold 79,000 ordinary shares in two open-market sales on Sept 21-22, 2026 at $97.8097-$100.7182 per share, leaving 410,209 shares owned.
BioNTech CEO and 10% owner Ugur Sahin sold 64,000 ordinary shares in two open-market sales on Sep 17-18, 2026, at $96.22-$98.60, leaving 489,209 shares.
BioNTech CEO Ugur Sahin sold 49,000 ordinary shares in 2 open-market sales on Sept 15-16, 2026, at $96.09-$96.49 per share, leaving 553,209 shares owned.
CEO and 10% owner Ugur Sahin sold 86,000 BioNTech ordinary shares in two open-market sales on Sep 11-14, 2026, at $96.9338-$99.4467 per share. He held 602,209 shares afterward.
BioNTech CEO Ugur Sahin sold 20,500 ordinary shares at $96.3067 on Sep 10, 2026, leaving 688,209 shares held.
Ugur Sahin, CEO of BioNTech, sold 73,000 ordinary shares in two open-market transactions on Sep 8-9, 2026, at prices between $97.78 and $99.20.
BioNTech SE CEO and 10% owner Ugur Sahin sold 45,000 ordinary shares on the open market on Sep 3, 2026, at $102.8496 per share, per a Form 4 filed Sep 8, 2026. He held 813,209 shares afterward.
Filings
57 · Latest SEC filingsBioNTech CEO Ugur Sahin sold 63,209 Ordinary Shares in two open-market sales on Oct 8-9, 2026, at $92.31-$95.37 per share, leaving 0 shares owned after.
BioNTech SE CEO Ugur Sahin sold 24,000 ordinary shares at $95.8597 on Oct 7, 2026, leaving 63,209 shares owned.
BioNTech CEO Ugur Sahin sold 93,000 ordinary shares in two open-market transactions on Oct 5-6, 2026, at prices of $96.81-$97.23, leaving 87,209 shares held.
BioNTech SE CEO Ugur Sahin sold 34,000 ordinary shares in two open-market sales on Oct 1-2, 2026 at prices from $96.72 to $97.46, leaving 180,209 shares held.
BioNTech CEO Ugur Sahin sold 66,000 ordinary shares in two open-market transactions on Sept 29-30, 2026, at prices of $98.12-$98.26 per share. He held 214,209 shares after the sales.
BioNTech CEO Ugur Sahin sold 61,000 ordinary shares in two open-market sales on Sept 25-28, 2026, at $98.47-$98.69 per share, leaving 280,209 shares held.
BioNTech CEO Ugur Sahin sold 69,000 ordinary shares on Sept 23-24, 2026 at $98.99-$99.40 per share (two open-market S-Sale transactions). After the sales he owned 341,209 shares.
BioNTech CEO Ugur Sahin sold 79,000 ordinary shares in two open-market sales on Sept 21-22, 2026 at $97.8097-$100.7182 per share, leaving 410,209 shares owned.
BioNTech CEO and 10% owner Ugur Sahin sold 64,000 ordinary shares in two open-market sales on Sep 17-18, 2026, at $96.22-$98.60, leaving 489,209 shares.
BioNTech CEO Ugur Sahin sold 49,000 ordinary shares in 2 open-market sales on Sept 15-16, 2026, at $96.09-$96.49 per share, leaving 553,209 shares owned.
CEO and 10% owner Ugur Sahin sold 86,000 BioNTech ordinary shares in two open-market sales on Sep 11-14, 2026, at $96.9338-$99.4467 per share. He held 602,209 shares afterward.
BioNTech CEO Ugur Sahin sold 20,500 ordinary shares at $96.3067 on Sep 10, 2026, leaving 688,209 shares held.
Ugur Sahin, CEO of BioNTech, sold 73,000 ordinary shares in two open-market transactions on Sep 8-9, 2026, at prices between $97.78 and $99.20.
BioNTech SE CEO and 10% owner Ugur Sahin sold 45,000 ordinary shares on the open market on Sep 3, 2026, at $102.8496 per share, per a Form 4 filed Sep 8, 2026. He held 813,209 shares afterward.
Director Susanne Schaffert filed a Form 3 with no shares acquired or disposed.
Director Low-Friedrich Iris Katharina filed a Form 3 with no reportable transactions; 0 shares acquired or disposed.
BioNTech COO Sierk Poetting received 12,586 options and 10,069 performance share units in a compensation award on 2026-05-12.
BioNTech officer received an award of options for 12,586 shares and performance share units for 10,069 shares.
On May 12, 2026, Annemarie Hanekamp, Chief Commercial Officer of BioNTech SE, was awarded 12,586 option shares and 10,069 performance share units at $0.00 each.
BioNTech CFO Ramon Zapata Gomez received 18,879 options and 15,103 performance share units as compensation on May 12, 2026.
BioNTech officer Jimenez Kylie received a grant: 10,488 stock options and 8,391 performance share units (award, no purchase).
Sierk Poetting, COO of BioNTech SE, sold 50,000 ordinary shares at $110.5592 each on April 22, 2026. He retained 399,387 shares directly.
BioNTech CEO Ugur Sahin filed a Form 3/A, showing no share acquisitions (0 shares). He retains 39,218,111 ordinary shares.
Director Rudolf Staudigl reported a Form 3 filing with no reportable transactions; 0 shares of Ordinary Shares were involved.
BioNTech CEO Ugur Sahin filed an initial Form 3 on 2026-03-25 listing 40,132,788 and 858,209 ordinary shares (plus 0-share entries), 57,253 stock options, 37,777 phantom options, and 23,434 performance share units. This is an initial ownership statement, not a purchase or sale.
A Form 3 was filed for director Nicola Claire Blackwood of BioNTech SE, with no shares acquired or disposed; 0 shares reported.
BioNTech SE director Anja Morawietz filed Form 3 on 2026-03-25. The two reported transactions involved 0 Ordinary Shares acquired at a $0.00 price, leaving holdings of 200 and 40 shares respectively.
Transcripts
PendingCompany news
Reuters, WSJ, Bloomberg and FT first, as far as our news provider delivers them; other publishers behind the second filter. Headlines link to the publisher.Company data
Company intelligence
Updated: Nov 21, 2026, 06:44 PM UTC
Company data
Company intelligence
Company profile
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- Ugur Sahin
- Employees
- 7,807
- IPO date
- Oct 10, 2019
- Country
- DE
- Exchange
- NASDAQ Global Select
Rating factors
- Return on equityi
- 1/5
- Return on assetsi
- 1/5
- Debt to equityi
- 4/5
- Price to earningsi
- 1/5
- Price to booki
- 4/5
Company press releases
Congressional disclosures
House
Market cap history
Largest fund holders
| Fund | Weight | Shares held |
|---|---|---|
| FCNKX | 0.23% | 4.7M |
| VHCAX | 0.69% | 2.2M |
| FBT | 2.89% | 1M |
| FEMKX | 0.67% | 854K |
| IBB | 0.57% | 746.1K |
| FLCNX | 0.18% | 706.8K |
| FPHAX | 1.69% | 308.2K |
| FDVLX | 0.24% | 262K |
| FPURX | 0.06% | 240.4K |
| FBIOX | 0.35% | 235.8K |
| FNDF | 0.06% | 183.4K |
| BDMIX | 0.1% | 153.7K |
Analyst track record
How the analysts covering BNTX have done: ratings, price-target accuracy and the measured reaction after their calls.
| 12 months | 3 years | |
|---|---|---|
| Ratings | 148 | 495 |
| Analysts | 25 | 30 |
| Buy / hold / sell | 129 / 19 / 0 | 380 / 108 / 7 |
| Upgrades / downgrades / initiations | 2 / 2 / 2 | 8 / 3 / 11 |
| Price targets hit / missed | 0 / 141 (0%) | 0 / 448 (0%) |
| Avg. return after a rating (TipRanks) | -35.7% | -36.4% |
| Best / worst call | -9.1% / -55.0% | -4.3% / -56.0% |
After buy calls on this stock: median 21-day move -1.0% vs S&P 500 -1.4% (n = 377)
Most accurate on this stock
Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.
- Daina GrayboschLeerink Partners73% hit rate on this stock · 11 targets measuredHoldtarget $113Feb 2, 2026
- Robert BurnsH.C. Wainwright46% hit rate on this stock · 28 targets measuredBuytarget $110Nov 9, 2026
- Emmanuel PapadakisDeutsche Bank7% hit rate on this stock · 14 targets measuredBuytarget $140Aug 26, 2026
Latest ratings
| Date | Analyst | Call | Target | |
|---|---|---|---|---|
| Nov 19, 2026 | Jessica FyeJ.P. MorganNov 19, 2026 | HoldMaintained | $93.00↗ | article ↗ |
| Nov 16, 2026 | Tazeen AhmadBank of America SecuritiesNov 16, 2026 | BuyMaintained | $108↗ | article ↗ |
| Nov 11, 2026 | Geoff MeachamCitiNov 11, 2026 | BuyMaintained | $125↗ | article ↗ |
| Nov 9, 2026 | Terence FlynnMorgan StanleyNov 9, 2026 | BuyReiterated | $106↗ | article ↗ |
| Nov 9, 2026 | Robert BurnsH.C. WainwrightNov 9, 2026 | BuyMaintained | $110↗ | article ↗ |
Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.
TipRanks data · computed Nov 20, 2026 · 148 ratings
BingX